Cystic fibrosis is a hereditary disease that affects a body’s secretory glands including lungs, pancreas, liver and intestines. The most common organ affected by cystic fibrosis is lungs. Cystic fibrosis leads to irregular secretions leading to accumulation of mucus which does not result in proper functioning of an affected organ. Cystic fibrosis diagnosis requires a physical therapy that helps remove the mucus and use antibiotics and enzymes to combat an organ infection. Cystic fibrosis is caused by gene mutation necessary for the transmembrane conductance regulator (CFTR) for the protein cystic fibrosis. Sweat, mucus, and body secretions are regulated by CFTR. Cystic fibrosis is identified by conducting sweat and genetic tests. Physical therapy is used to treat cystic fibrosis patients including reduction in the production of mucus among others to combat against organ infections. Furthermore, cystic fibrosis therapy involves the use of medications such as Pulmozyme, a drug manufactured by Roche Holding AG, a pharmaceutical company based in Switzerland and Kalydeco, a drug manufactured by Vertex Pharmaceuticals Incorporated, among others. The medication for cystic fibrosis can be administered to a patient by various routes such as oral and inhalation is increasing the demand in global cystic fibrosis market.
Read More about this Market @ https://www.absolutemarketsinsights.com/reports/Cystic-Fibrosis-Market-2019-2027-520
Many new drug developments with improved effectiveness, and outcomes are expected to offer good opportunities for the market for cystic fibrosis treatment. To quote for instance, the United States, food and drug administration (FDA) has approved a new drug “Trikafta” from Vertex Pharmaceuticals, Inc., to treat cystic fibrosis patient. Trikafta is first triple combination therapy drug containing three CFTR modulators and they are Elexacaftor, tezacaftor, and ivacaftor. The drug has passed through the two clinical trials, treating 510 cystic fibrosis patients. In the research it is found that, patient who took “Trikafta” has improved their breathing by 13.8% compared who took another medicine placebo and in second trail 10% improvement in breathing has been recorded thus leading to increase in demand for global cystic fibrosis market.
The report provides both qualitative and quantitative research of cystic fibrosis market as well as provides comprehensive insights and development methods adopted by the prominent market players. Some of the key market participants in the cystic fibrosis market are AbbVie Inc, Aradigm Corporation, Celtaxsys Aus Pty Limited, CHIESI Farmaceutici S.p.A., Demegen, Inc. Digestive Care, Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc, GlaxoSmithKline Plc., Grifols, S.A., Mylan N.V., Pharmaxis Ltd., Polydex Pharmaceuticals Limited, PTC Therapeutics, Vertex Pharmaceuticals Incorporated amongst others. Major market players are offering their solution with new technologies and integrated point of sales solutions to retailers, pharmacies, hospitals, etc. An increase in the incidence of cystic fibrosis has resulted in the need for modern and innovative medical therapies. This has led to an increase in the number of pipeline drugs on the market, which in the forecast period is projected to provide remunerative incentives for business expansion. For each company, the report studies their global presence, competitors, and product offerings, among others.
Global Cystic Fibrosis Market:
- By Drugs Class
- CFTR Modulators
- Mucolytics (Mucoactive Drugs) and Bronchodilators
- Antibiotics
- Pancreatic Enzyme Replacement Therapy (PERT)
- By Route of Administration
- Oral
- Inhaled drugs
- By Form
- Powder
- Liquid
- Capsule
- Tablet
- By Distribution Channel
- Offline Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Offline Pharmacies
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Contact Us:
Company: Absolute Markets Insights
Email id: sales@absolutemarketsinsights.com
Phone: +91-740-024-2424
Contact Name: Shreyas Tanna
Website: https://www.absolutemarketsinsights.com